Figure 1.

Characterization of LCP-AEAA Nanoparticles and In Vivo Uptake on KPC Tumor

(A) Pharmacokinetics of intravenously (i.v.) injected LCP-AEAA by ¹⁷⁷Lu (n = 3) radiolabeling. (B and C) LCP-AEAA nanoparticles with Cy5-labeled oligo encapsulated in the core were i.v. injected into mice bearing KPC-RFP/Luc (KPC cell line transfected with mCherry red fluorescent protein and firefly luciferase) tumor (n = 3). The Cy5-positive population within different cell types in the tumor is shown. (B) Mice were sacrificed 18 hr post-injection, and the % of Cy5-positive cells in each cell population was quantified by flow cytometry. (C) Representative flow cytometry graphs for RFP-positive Cy5-positive cells are shown. (D and E) Biodistribution of ¹⁷⁷Lu LCP-AEAA nanoparticles 24 hr post-intravenous administration (n = 3). Percent of injected dose (D) and percent of injected dose per gram of tissue (E) are reported. Data are presented as mean ± SEM.